Norchi Discusses Significance of Clinical Data, CE Mark Process and Additional Corporate Highlights
FRAMINGHAM, MA–(Marketwired – Aug 19, 2016) – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced its President and CEO, Terrence Norchi, MD conducted an interview with Dave Donlin, the host of Publicwire.com’s “Small Cap Spotlight” podcast. Dr. Norchi discussed, the Company’s lead product candidate, the AC5 Topical Hemostatic Device™ (“AC5”), the results of the Company’s recent clinical study of AC5 and its current plans for submitting a CE Mark application, among other topics. The podcast has been posted on the Company’s website and is accessible at http://www.archtherapeutics.com/news/media.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform with the goal of making surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidates, known as the AC5 Surgical Hemostatic Device™ and AC5 Topical Hemostatic Device™, are being designed to achieve hemostasis in surgical procedures.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.